drugset / Trial / NCT00489372

Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

NCT00489372

Phase 1 Completed 36 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.

Timeline

Start
2007-07
Primary completion
2008-03
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylselenocysteine Other / unclassified Oral

Indications

No indication recorded.